Integra LifeSciences (NASDAQ:IART) Rating Increased to Neutral at BTIG Research

Integra LifeSciences (NASDAQ:IART) was upgraded by equities research analysts at BTIG Research from a “sell” rating to a “neutral” rating in a research note issued to investors on Monday, MarketBeat.com reports.

Other equities analysts also recently issued research reports about the stock. Citigroup decreased their price objective on shares of Integra LifeSciences from $20.00 to $16.00 and set a “sell” rating for the company in a report on Tuesday, October 1st. Truist Financial decreased their price objective on shares of Integra LifeSciences from $32.00 to $26.00 and set a “hold” rating for the company in a report on Tuesday, July 30th. Morgan Stanley lifted their price objective on shares of Integra LifeSciences from $24.00 to $27.00 and gave the stock an “underweight” rating in a report on Monday, July 15th. Finally, JMP Securities decreased their price objective on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a report on Tuesday, July 30th. Three research analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, Integra LifeSciences currently has an average rating of “Hold” and a consensus price target of $27.13.

Integra LifeSciences Stock Up 0.3 %

Shares of NASDAQ:IART opened at $17.49 on Monday. The company has a current ratio of 3.39, a quick ratio of 2.10 and a debt-to-equity ratio of 1.17. The company has a fifty day simple moving average of $19.61 and a 200 day simple moving average of $26.30. The firm has a market cap of $1.38 billion, a PE ratio of 34.98, a price-to-earnings-growth ratio of 0.60 and a beta of 1.09. Integra LifeSciences has a 12-month low of $16.81 and a 12-month high of $45.42.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Monday, July 29th. The life sciences company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.01. The business had revenue of $418.20 million during the quarter, compared to analyst estimates of $413.07 million. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. The business’s revenue was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.71 earnings per share. On average, equities research analysts anticipate that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Hedge Funds Weigh In On Integra LifeSciences

Several hedge funds and other institutional investors have recently modified their holdings of IART. Blue Trust Inc. lifted its holdings in Integra LifeSciences by 100.5% in the second quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock worth $26,000 after purchasing an additional 444 shares during the period. CWM LLC increased its holdings in shares of Integra LifeSciences by 50.8% in the 2nd quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock valued at $37,000 after purchasing an additional 425 shares during the period. Valley National Advisers Inc. acquired a new position in shares of Integra LifeSciences in the 1st quarter valued at about $63,000. Canada Pension Plan Investment Board acquired a new position in shares of Integra LifeSciences in the 2nd quarter valued at about $114,000. Finally, Allspring Global Investments Holdings LLC increased its holdings in shares of Integra LifeSciences by 58.0% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 4,662 shares of the life sciences company’s stock valued at $136,000 after purchasing an additional 1,711 shares during the period. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.